PulseAugur
LIVE 09:10:51
meme · [1 source] · · 中文(ZH) 马应龙:子公司获得溴芬酸钠滴眼液药品注册证书

Ma Ying Long subsidiary gets drug registration for eye drops

Ma Ying Long's subsidiary has received a drug registration certificate for Bromfenac Sodium Eye Drops from China's National Medical Products Administration. This medication is intended for the symptomatic treatment of inflammatory conditions affecting the outer and anterior parts of the eye, such as conjunctivitis and scleritis. In separate news, Korea Post is increasing its investment in high-yield assets like AI data centers and European real estate to offset losses in its traditional postal business. AI

Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →

RANK_REASON The cluster contains unrelated news items about a drug registration and investment strategies, lacking a cohesive central theme or significant event.

Read on 36氪 (36Kr) →

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Mayinglong: Subsidiary Obtains Drug Registration Certificate for Bromfenac Sodium Eye Drops

    36氪获悉,马应龙公告,近日,公司子公司江西马应龙美康药业有限公司收到国家药品监督管理局核准签发的溴芬酸钠滴眼液《药品注册证书》。溴芬酸钠滴眼液用于外眼部和前眼部的炎症性疾病的对症治疗(结膜炎、巩膜炎、术后炎症)。